PUBLISHER: Grand View Research | PRODUCT CODE: 1842107
PUBLISHER: Grand View Research | PRODUCT CODE: 1842107
The global HPV associated disorders market size was estimated at USD 18.5 billion in 2024 and is projected to reach USD 28.5 billion by 2033, growing at a CAGR of 4.9% from 2025 to 2033. The industry is witnessing strong growth due to the rising prevalence of HPV infections worldwide.
Persistent HPV infections are recognized as a major cause of cervical, anal, vulvar, vaginal, penile, and oropharyngeal cancers, which has increased the need for timely diagnosis and treatment. Growing demand for molecular diagnostic tests that can accurately detect high-risk HPV strains is fueling adoption in clinical settings, while healthcare systems are prioritizing screening programs to identify precancerous changes early. For instance, in March 2024, World Health Organization findings indicated that human papillomavirus (HPV) encompassed a group of around 200 known viruses, with most infections remaining harmless while some high-risk types caused genital warts and various cancers. In approximately 90% of cases, the body naturally cleared the infection. In 2019, HPV was estimated to have caused about 620,000 cancer cases in women and 70,000 in men. Cervical cancer became the fourth leading cause of cancer among women in 2022, with 660,000 new cases and 350,000 deaths globally. Cervical cancers represented over 90% of all HPV-related cancers in women. These figures highlight the substantial global burden of HPV-related disease, strengthening the demand for advanced diagnostics and effective treatments.
Advancements in treatment solutions represent another major growth driver for the HPV associated disorders market. Innovative therapies, including immunotherapies and targeted drugs, are gaining traction as they provide improved outcomes for patients with HPV-driven malignancies. Pharmaceutical companies are investing heavily in research and development to bring novel therapies into the landscape, strengthening the treatment pipeline. For instance, in April 2025, authors at BioMed Central Ltd. reported that human papillomavirus (HPV), a DNA virus, had been established as a causative agent of cervical, vulvar, vaginal, penile, anal, and head & neck cancers. They noted that persistent infection and the oncogenic potential of certain HPV genotypes drove most HPV-related cancers.
Global HPV Associated Disorders Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global HPV associated disorders market report based on type, treatment, distribution channel, and region: